APLS · As filed with the SEC
Apellis Pharmaceuticals balance sheet, by fiscal year
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 466,233,000 | 411,290,000 | 351,185,000 | 551,801,000 |
| Accounts receivable | 366,221,000 | 264,926,000 | 206,442,000 | 7,727,000 |
| Inventory | 142,556,000 | 81,404,000 | 146,362,000 | 85,714,000 |
| Prepaid assets | — | 18,368,000 | 38,820,000 | 36,350,000 |
| Prepaid and other current assets | 38,303,000 | — | — | — |
| Restricted cash | 1,527,000 | 1,322,000 | 1,114,000 | 1,273,000 |
| Other current assets | — | 11,644,000 | 22,408,000 | 36,658,000 |
| Total current assets | 1,014,840,000 | 788,954,000 | 766,331,000 | 719,523,000 |
| Non-current assets: | ||||
| Right-of-use assets | 18,195,000 | 16,083,000 | 16,745,000 | 18,747,000 |
| Property and equipment, net | 1,708,000 | 2,952,000 | 4,345,000 | 6,148,000 |
| Long-term inventory | 34,959,000 | 75,713,000 | — | — |
| Other assets | 5,555,000 | 1,349,000 | 1,309,000 | 15,799,000 |
| Total assets | 1,075,257,000 | 885,051,000 | 788,730,000 | 760,217,000 |
| Liabilities and Stockholders’ Equity | ||||
| Current liabilities: | ||||
| Accounts payable | 56,798,000 | 38,572,000 | 37,516,000 | 37,342,000 |
| Accrued expenses | 166,049,000 | 140,184,000 | 127,806,000 | 95,139,000 |
| Convertible senior notes | 93,662,000 | — | — | — |
| Current portion of development liability | — | — | 75,830,000 | 29,504,000 |
| Current portion of lease liabilities | 7,087,000 | 6,753,000 | 6,441,000 | 5,625,000 |
| Total current liabilities | 323,596,000 | 185,509,000 | 247,593,000 | 167,610,000 |
| Long-term liabilities: | ||||
| Long-term development liability | — | — | 239,817,000 | 315,647,000 |
| Long-term credit facility | 361,664,000 | 359,489,000 | — | — |
| Convertible senior notes | 0 | 93,341,000 | 93,033,000 | 92,736,000 |
| Lease liabilities | 11,947,000 | 10,201,000 | 11,454,000 | 14,352,000 |
| Other liabilities | 7,903,000 | 7,972,000 | 2,312,000 | — |
| Total liabilities | 705,110,000 | 656,512,000 | 594,209,000 | 590,345,000 |
| Stockholders’ equity: | ||||
| Preferred stock, $0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 200,000 shares authorized at December 31, 2025 and 2024; 126,621 and 124,495 shares issued and outstanding at December 31, 2025 and 2024, respectively | 12,000 | 12,000 | 12,000 | 11,000 |
| Additional paid-in capital | 3,385,216,000 | 3,267,201,000 | 3,035,539,000 | 2,479,596,000 |
| Accumulated other comprehensive loss | (2,103,000) | (3,308,000) | (3,542,000) | (875,000) |
| Accumulated deficit | (3,012,978,000) | (3,035,366,000) | (2,837,488,000) | (2,308,860,000) |
| Total stockholders’ equity | 370,147,000 | 228,539,000 | 194,521,000 | 169,872,000 |
| Total liabilities and stockholders’ equity | 1,075,257,000 | 885,051,000 | 788,730,000 | 760,217,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.